Contrafect Corporation · OTC:CFRXQ
Contrafect — Investor Presentation (June 2016)
34 slides from Contrafect's investor presentation, Jun 27, 2016
Slide 1: First in Class Anti-Infectives for Life-Threatening, Drug Resistant Infections
©2016 ContraFect Corporation June, 2016 First in Class Anti-Infectives for Life- Threatening, Drug Resistant Infections Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could
Slide 3: ContraFect Summary
ContraFect Summary First in Class Anti-Infectives for Life-Threatening, Drug Resistant Infections Lysin Platform: A Novel Alternative to Conventional Antibiotics Bacteriophage-Derived Enzyme Biologics with Potent, Selective Antibacterial Activity Developed Internally and Collaboratively with The Roc
Slide 4: The Threat of Antibiotic Resistance
The Threat of Antibiotic Resistance… “…the world is headed for a post-antibiotic era…” - Dr. Keiji Fukuda, WHO “…one of our most serious health threats.” - Dr. Tom Frieden, CDC “…back into the dark ages of medicine where treatable infections and injuries will kill once again.” - David Cameron, UK Pr
Slide 5: Drug Resistance is a Global Crisis Today
Drug Resistance is a Global Crisis Today Significant Burden of Drug Resistant Infections Sharp Decline in Antibiotic Development New Antibiotic Drug Approvals Years
Slide 6: The Right Time to Invest in Anti-Infectives
The Right Time to Invest in Anti-Infectives Predictive Efficacy *Legislation Pending Favorable Climate Regulatory Legislation GAIN Act QIDP – Fast Track, Priority Review, Exclusivity ADAPT/PATH Act* Limited population pathway Streamlined approval DISARM Act* Improved reimbursement Non-Dilutive Fundi
Slide 7: Lysin Technology
Lysin Enzyme Derived From Bacteriophage Cleaves Peptidoglycan Cell Wall of Bacteria Used by Bacteriophage to Release New Phage Particles After Replication, Killing the Host Bacteria Molecular Weight ~20-30KD Synthetic, Recombinant Manufacture Not a Bacteriophage! Lysin Technology
Slide 8: Lysins: Breakthrough Alternative to Antibiotics
Unique Anti-Bacterial Action Protein Therapeutic – Enzyme, NOT Inhibitor Potent, Rapidly Cidal Pathogen Targeted, not Broad Spectrum Low propensity for Effects on Microbiome – e.g., C. Difficile Active Against Biofilms – Currently no Approved Agents to Treat Biofilms Strong Resistance Profile Active
Slide 9: Lysins: Rapid Bactericidal Action
Lysins: Rapid Bactericidal Action
Slide 10: CF-301 Breakthrough Alternative to Antibiotics for Staph Aureus Infections
CF-301 Breakthrough Alternative to Antibiotics for Staph Aureus Infections
Slide 11: CF-301: Targeting Invasive Staph aureus Infections Including MRSA
Indication: CF-301 for the Treatment of Staph aureus Bloodstream Infections, Including Endocarditis, Used in Combination with Standard of Care Antibiotics 119,000 Hospitalizations* Average Length of Stay - 21 days Average Hospital Cost - $114,000 30,000 Deaths* CF-301: Targeting Invasive Staph aureu
Slide 12: CF-301 Is A Novel Anti-Staphylococcal Agent
Bactericidal Cell Wall Hydrolase Produced Recombinantly 26 kDa Exclusive, World-Wide License for Therapeutic Use in Humans from The Rockefeller University Composition of Matter Patent Expires in 2032 Staph aureus Peptidoglycan CF-301 Is A Novel Anti-Staphylococcal Agent
Slide 13: Rapid, Potent & Targeted Killing
Rapid, Potent & Targeted Killing Active against MRSA, VRSA, DRSA Strains Low propensity for Resistance Development Clears Biofilms Synergistic with Antibiotics CF-301 Is A Novel Anti-Staphylococcal Agent
Slide 14: Rapidly Cidal; Efficacious In vitro and In vivo
Control CF-301 VAN DAP In vitro Timekill (1X MIC) LOD Rapid, Potent & Targeted Killing In vivo efficacy - Mouse Bacteremia Model: CF-301 Dose Response as Mono-therapy % survival BUFFER 0.025 mg/kg 0.5 mg/kg 2.5 mg/kg *LOD = Limit of Detection Source: Schuch et al JID 2014:209 Rapidly Cidal; Efficaci
Slide 15: Highly Targeted to Staph and Strep Pathogens
Gram Positive Gram Negative >512 Rapid, Potent & Targeted Killing CF-301 Is A Novel Anti-Staphylococcal Agent Source: Schuch et al JID 2014:209 Highly Targeted to Staph and Strep Pathogens No Effect on Gram Negative Pathogens (low C. difficile risk)
Slide 16: No Cross-Resistance to Other Antibiotics
No Cross-Resistance to Other Antibiotics Active Against MRSA, VRSA, DRSA Strains Strain (n=147) CF-301 Daptomycin Vancomycin Linezolid MRSA (120) + + + + DRSA (8) + - + + VRSA (14) + + - + LRSA (5) + + + - CF-301 Activity CF-301 Is A Novel Anti-Staphylococcal Agent Source: Schuch et al JID 2014:209
Slide 17: Low Propensity for Resistance Development
In vitro Serial Passage Resistance Studies Very Difficult to Find Resistant Mutants in Serial Passage Combination Reduces Resistance Emergence to SOC Antibiotic Low Propensity for Resistance Development CF-301 Is A Novel Anti-Staphylococcal Agent Source: Schuch et al JID 2014:209
Slide 18: Biofilms: A Major Medical Problem
Biofilms: A Major Medical Problem Biofilms Complicate the Treatment of Invasive Staph Aureus Infections Including: Heart Valves, Catheters and Prosthetic Devices Composed of Bacterial Cells and Matrix Shields Bacteria From Immune System and Conventional Antibiotics Persister (Dormant) Bacteria Refra
Slide 19: Clears Biofilms
MRSA-Infected Catheter with Biofilm Before Exposure to CF-301 15 min Exposure to CF-301 Clears Biofilms CF-301 Is A Novel Anti-Staphylococcal Agent Source: ICAAC Poster 2013
Slide 20: Synergistic with Antibiotics
In vitro Timekill (< 1x MIC) In vivo Survival (mouse) (high inoculum model) Combination with SOC Provides Maximum Killing CF-301 Is A Novel Anti-Staphylococcal Agent Source: Schuch et al JID 2014:209 Synergistic with Antibiotics
Slide 21: Synergistic with SOC Antibiotics: Rat Endocarditis Model
Daptomycin Alone at Human Therapeutic Equivalent Dose Daily x 4 Days 3 log reduction in CFUs Single Dose of CF-301 Plus Daptomycin Daily Dose x 4 Days 6 log reduction in CFUs p≤0.001 vs. Dap alone 4/9 Rats Tested Culture-Negative Tissues with CF-301/DAP Combo Vegetations, Kidney, Spleen 9/9 DAP Mono
Slide 22: CF-301 Phase 1 Clinical Trial Study Design
CF-301 Phase 1 Clinical Trial Study Design Evaluated Safety, Tolerability, and Pharmacokinetics (PK) of CF-301 Healthy Volunteers – Four Dosing Cohorts Placebo-controlled, Double-blind, Dose-escalating Study Single Dose Administered as a 2-hour IV Infusion
Slide 23: CF-301 Phase 1 Clinical Trial Results
CF-301 Phase 1 Clinical Trial Results 20 Subjects Enrolled Across 4 Dosing Cohorts (0.04, 0.12, 0.25, 0.40 mg/kg) Well behaved pharmacokinetic (PK) profile Linear and Intra-subject Variability Was Low Well Tolerated No Serious AEs, No Study Stopping Rules Met, No CF-301-related Hypersensitivity AEs
Slide 24: CF-301 Phase 2 Study
CF-301 Phase 2 Study Indication For the Treatment of Adults with Complicated Bacteremia, Including Endocarditis, Caused by MRSA or MSSA, Used in Combination with Conventional Antibacterial Therapy Design Superiority Comparison: CF-301 + Standard of Care (SOC) vs Placebo + SOC International, Multicen
Slide 25: CF-404 Triple Antibody Cocktail for Serious Influenza Infection
CF-404 Triple Antibody Cocktail for Serious Influenza Infection
Slide 26: CF-404 MAb Cocktail for Influenza
Substantial Market Opportunity Targets Unchanging Regions of Hemagglutinin Combination Antibody Therapy Extends Time-to-Treat Window Targeting IND Submission in Mid-2017 CF-404 MAb Cocktail for Influenza
Slide 27: Substantial Market Opportunity
Flu Season US Flu-Related Hospitalizations High Unmet Medical Need: Up to 49,000 Deaths/Yr* Thousands * Most Recent Data ‘06/’07 Flu Season Source: CDC Estimates Substantial Market Opportunity CF-404 MAb Cocktail for Influenza
Slide 28: Targets Unchanging Regions of Hemagglutinin
H1 - 1918 H1 - 2009 Indicates Point of Mutation Indicates Conserved Target Region Targets Unchanging Regions of Hemagglutinin CF-404 MAb Cocktail for Influenza
Slide 29: Extends Time to Treat Window
% Survival Time to Initiate Therapy Tamiflu (Twice Daily x 5) CF-404 (Single Dose) Mice with H1N1 Influenza (Survival at 14 Days) Source: ContraFect Unpublished Data CF-404 MAb Cocktail for Influenza Extends Time to Treat Window
Slide 30: Team Track Record of Creating Shareholder Value
Team Track Record of Creating Shareholder Value Steven C. Gilman, Ph.D. – Chairman and CEO Former EVP, R&D and CSO, Cubist Pharmaceuticals Natalie Bogdanos – General Counsel & Corporate Secretary Assoc General Counsel Memorial Sloan-Kettering; General Counsel Enzo Biochem Cara Cassino, MD FCCP – CMO
Slide 31: Summary Financial Data
Summary Financial Data IPO July 29, 2014: $41.3 M PIPE Financing June 12, 2015: $20 M Oracle/Broadfin/Birchview/Cormorant Cash and Investments at March 31, 2016: $26.3 M Shares Outstanding: 27.5 M
Slide 32: Upcoming Milestones and Events
Upcoming Milestones and Events Phase 1 Trial Details 2Q16 Advance New Lysin to Clinical Candidate 2Q16 Initiate Phase 2 Clinical Trial for CF-301 4Q16 IND Submission for CF-404 Mid-2017 Phase 2 Topline Data Readout for CF-301 2Q18
Slide 33: Investment Highlights
Investment Highlights Novel Anti-Infective Technologies that Address Drug-Resistance Lysins: Potential Breakthrough Alternatives to Antibiotics CF-301: for Staph aureus Infections Including MRSA First and Only Lysin to Enter Clinical Trials in the U.S. Granted Fast Track Status by FDA Phase 1 comple
Slide 34: ContraFect Corporation
ContraFect Corporation NASDAQ: CFRX